Last reviewed · How we verify
VAS203
VAS203 is a nitric oxide synthase inhibitor that reduces nitric oxide production to protect against ischemic brain injury.
VAS203 is a nitric oxide synthase inhibitor that reduces nitric oxide production to protect against ischemic brain injury. Used for Acute ischemic stroke.
At a glance
| Generic name | VAS203 |
|---|---|
| Also known as | Ronopterin |
| Sponsor | veriNOS operations GmbH |
| Drug class | Nitric oxide synthase inhibitor |
| Target | Nitric oxide synthase (NOS) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
VAS203 selectively inhibits nitric oxide synthase, an enzyme that produces nitric oxide. Excessive nitric oxide production during ischemic stroke contributes to neuronal damage through oxidative stress and inflammation. By reducing nitric oxide levels, VAS203 aims to limit secondary brain injury and improve neurological outcomes in acute ischemic stroke patients.
Approved indications
- Acute ischemic stroke
Common side effects
- Hypertension
- Headache
- Nausea
Key clinical trials
- Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury (PHASE3)
- Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers (PHASE1)
- Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAS203 CI brief — competitive landscape report
- VAS203 updates RSS · CI watch RSS
- veriNOS operations GmbH portfolio CI